ondansetron has been researched along with fosaprepitant in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Borms, M; Carides, AD; Cocquyt, V; De Smet, M; Decramer, ML; Eldridge, K; Gertz, BJ; O'Brien, M; Reinhardt, RR; Schellens, JH; Van Aelst, F; Van Belle, S; Verbeke, L | 1 |
| Brestan, E; Bui, B; Carides, AD; De Smet, M; Decramer, ML; Eldridge, K; Evans, JK; Garin, AM; Gertz, BJ; Lichinitser, MR; Michiels, N; Navari, RM; Reinhardt, RR; Riviere, A; Thant, M; Van Belle, S | 1 |
| Aapro, M; Carides, AD; Evans, JK; Hargreaves, R; Hesketh, PJ; Horgan, KJ; Naylor, RJ; Tattersall, FD; Van Belle, S | 1 |
| Beckford, E; Boice, JA; Carides, A; Chua, D; DeVandry, S; Dinis, J; Grunberg, S; Hardwick, JS; Herrstedt, J; Maru, A; Roila, F; Taylor, A | 1 |
| Hamaguchi, E; Kakuta, N; Kume, K; Soga, T; Tanaka, K; Tsutsumi, R; Tsutsumi, YM | 1 |
| Fukuta, K; Hamaguchi, E; Kakuta, N; Kawanishi, R; Kume, K; Soga, T; Tanaka, K; Tsutsumi, R; Tsutsumi, YM | 1 |
| Hamaguchi, E; Kakuta, N; Kume, K; Mita, N; Tanaka, K; Tsutsumi, R; Tsutsumi, YM | 1 |
| Agajanian, R; Cooper, W; Dakhil, C; Gabrail, NY; Klepper, MJ; Mosier, MC; Payne, JY; Schnadig, ID; Schwartzberg, LS; Smith, RE; Taylor, C; Vacirca, JL; Wilks, ST | 1 |
| Kakuta, N; Kasai, A; Kume, K; Murakami, C; Oyama, T; Sakai, Y; Tanaka, K; Tsutsumi, YM | 1 |
| Beckford-Brathwaite, E; Camacho, E; Green, SA; Jordan, K; Khanani, S; Noga, SJ; Pong, A; Rapoport, BL; Weinstein, C | 1 |
| Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C | 1 |
| Binder, V; Blaeschke, F; Cabanillas Stanchi, KM; Döring, M; Feucht, J; Feuchtinger, T; von Have, M; Willier, S | 1 |
2 review(s) available for ondansetron and fosaprepitant
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Granisetron; Humans; Morpholines; Neoplasms; Neurokinin-1 Receptor Antagonists; Neurotransmitter Agents; Ondansetron; Prodrugs; Serotonin; Serotonin Antagonists; Substance P; Vomiting | 2003 |
9 trial(s) available for ondansetron and fosaprepitant
| Article | Year |
|---|---|
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Topics: Acetals; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Patient Satisfaction; Prodrugs; Vomiting | 2001 |
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Vomiting | 2002 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Treatment Outcome; Vomiting | 2011 |
The effects of intravenous fosaprepitant and ondansetron for the prevention of postoperative nausea and vomiting in neurosurgery patients: a prospective, randomized, double-blinded study.
Topics: Adult; Aged; Aged, 80 and over; Demography; Double-Blind Method; Female; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Neurosurgery; Ondansetron; Postoperative Care; Postoperative Nausea and Vomiting; Prospective Studies; Young Adult | 2014 |
Fosaprepitant versus ondansetron for the prevention of postoperative nausea and vomiting in patients who undergo gynecologic abdominal surgery with patient-controlled epidural analgesia: a prospective, randomized, double-blind study.
Topics: Adult; Analgesia, Epidural; Analgesia, Patient-Controlled; Analgesics, Opioid; Androstanols; Antiemetics; Double-Blind Method; Female; Fentanyl; Gynecologic Surgical Procedures; Humans; Middle Aged; Morpholines; Ondansetron; Pain; Piperidines; Postoperative Nausea and Vomiting; Postoperative Period; Prospective Studies; Remifentanil; Rocuronium | 2015 |
The effects of intravenous fosaprepitant and ondansetron in the prevention of postoperative nausea and vomiting in patients who underwent lower limb surgery: a prospective, randomized, double-blind study.
Topics: Administration, Intravenous; Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Female; Humans; Lower Extremity; Male; Middle Aged; Morpholines; Ondansetron; Postoperative Nausea and Vomiting; Prospective Studies | 2015 |
APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Granisetron; Humans; Injections, Subcutaneous; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Treatment Outcome; Vomiting; Young Adult | 2016 |
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Ondansetron; Vomiting | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Melphalan; Middle Aged; Morpholines; Nausea; Olanzapine; Ondansetron; Podophyllotoxin; Vomiting | 2018 |
2 other study(ies) available for ondansetron and fosaprepitant
| Article | Year |
|---|---|
A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis.
Topics: Adult; Aged; Aged, 80 and over; Databases as Topic; Demography; Humans; Middle Aged; Morpholines; Ondansetron; Postoperative Care; Postoperative Nausea and Vomiting; Retrospective Studies; Risk Factors; Young Adult | 2017 |
Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Case-Control Studies; Child; Child, Preschool; Feasibility Studies; Female; Humans; Infant; Male; Morpholines; Nausea; Neoplasms; Ondansetron; Patient Safety; Treatment Outcome; Vomiting | 2019 |